Lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo

Sun,Peng; Yu,Hong; Zhang,Wen-Qing; Hu,Ming; Lv,Rui

doi:10.3892/or.2012.1966

Lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo

Authors:
- Peng Sun
- Hong Yu
- Wen-Qing Zhang
- Ming Hu
- Rui Lv
View Affiliations

Affiliations: Department of Medical Microbiology, Medical College, Qingdao University, Qingdao 266071, P.R. China
Published online on: August 10, 2012 https://doi.org/10.3892/or.2012.1966
Pages: 1687-1692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF), a crucial promoter of blood vessel growth, not only stimulates endothelial cell proliferation, migration and survival, but also increases vascular permeability. The promotion of angiogenesis is a well-known prerequisite for tumor growth, invasion and metastasis. Evidence has shown that VEGF is overexpressed in many types of tumor tissues. Small interfering RNA (siRNA) targeting VEGF may effectively suppress cell proliferation and induce apoptosis in tumor cells. In this study, we aimed to evaluate whether lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo. The transfection of VEGF siRNA into SGC7901 human gastric cancer cells downregulated the expression of VEGF and Bcl-2, but upregulated the expression of p21. In a nude mouse model of subcutaneous xenografts, 24 days after VEGF siRNA treatment, the tumor volume and weight were significantly smaller in the VEGF siRNA group compared to the control scrambled siRNA group. Furthermore, the expression of VEGF, sirtuin 1 (SIRT1), survivin and Bcl-2 was downregulated, whereas the expression of p53 and p21 was upregulated in the tumor cells, indicating that VEGF siRNA induced apoptosis in gastric cancer cells by inhibiting SIRT1 expression, leading to p53 transcriptional upregulation and the activation of downstream p21, while suppressing Bcl-2 and survivin expression. Our results demonstrate that lentivirus-mediated siRNA targeting VEGF offers a potential strategy to prevent the growth of gastric cancer.

View Figures

View References

1	Claerhout S, Lim JY, Choi W, et al: Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLOS One. 6:e246622011. View Article : Google Scholar : PubMed/NCBI
2	Gong Y, Guo MZ, Ye ZJ, Zhang XL, Zhao YL and Yang YS: Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer. World J Gastroenterol. 17:526–533. 2011. View Article : Google Scholar : PubMed/NCBI
3	Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK and Bast RC Jr: Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 7:3747–3758. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hanson J, Gorman J, Reese J and Fraizer G: Regulation of vascular endothelial growth factor, VEGF gene promoter by the tumor suppressor, WT1. Front Biosci. 12:2279–2290. 2007. View Article : Google Scholar : PubMed/NCBI
5	Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G and Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61:5736–5740. 2001.PubMed/NCBI
6	Matsuura M, Onimaru M, Yonemitsu Y, et al: Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol. 175:1709–1721. 2009. View Article : Google Scholar
7	Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D and Detmar M: Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-c block its interaction with VEGF receptor-2 and 3. PLoS One. 5:e119412010. View Article : Google Scholar
8	Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G and Lee WM: Effect of VEGF and VEGF trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther. 10:1326–1333. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zheng LF, Li YJ, Wang H, Zhao JL, Wang XF and Hu YS: Combination of vascular endothelial growth factor antisense oligonucleotied therapy and radiotherapy increases the curative effects against maxillofacial VX2 tumors in rabbits. Eur J Radio. 78:272–276. 2011. View Article : Google Scholar
10	Yin YM, Yu H, Zhou YB, Zhang WQ and Lv R: Effects of lentivirus-mediated RNA interference on VEGF expression in human gastric cancer cells. Shandong Med J. 49:51–53. 2009.(In Chinese).
11	Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA and Schonfelder G: A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA. 103:1406–1411. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hoeben A, Landuyt B, Highley MS, Wildiers H, Oosterom AT and Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Lu Z, Wientjes MG and Au JL: Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12:492–503. 2010. View Article : Google Scholar : PubMed/NCBI
14	Guo P, Coban O, Snead N, Trebley J, Hoeprich S, Guo S and Shu Y: Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 62:650–666. 2010. View Article : Google Scholar : PubMed/NCBI
15	Guan HT, Xue XH, Dai ZJ, Wang XJ, Li A and Qin ZY: Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol. 12:2901–2907. 2006.PubMed/NCBI
16	Yao L, Liu F, Hong L, Sun L, Liang S, Wu K and Fan DM: The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res. 30:132011. View Article : Google Scholar : PubMed/NCBI
17	Sun P, Gao J, Liu YL, Wei LW, Wu LP and Liu ZY: RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem. 308:161–168. 2008. View Article : Google Scholar
18	Kim SH, Lee SH, Tian H, Chen X and Park TG: Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes. J Drug Target. 17:311–317. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hasan MR, Ho SH, Owen DA and Tai IT: Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer. 129:2115–2123. 2011. View Article : Google Scholar : PubMed/NCBI
20	Raskopf E, Vogt A, Sauerbruch T and Schmitz V: siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 49:977–984. 2008. View Article : Google Scholar : PubMed/NCBI
21	Sun P, Yu H, Zhang WQ, Liu Y and Lv R: Mechanism of the apoptosis of human gastric cancer cell line SUN SGC7901 induced by vascular endothelial growth factor siRNA. J Med Postgrad. 24:350–353. 2011.(In Chinese).
22	Bredow S, Juri DE, Cardon K and Tesfaigzi Y: Identification of a novel Bcl-2 promoter region that counteracts in a p53-dependent manner the inhibitory p2 region. Gene. 404:110–116. 2007. View Article : Google Scholar : PubMed/NCBI
23	Guha M and Altieri DC: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 8:2708–2710. 2009. View Article : Google Scholar : PubMed/NCBI
24	Deng CX: SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 5:147–152. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yamakuchi M and Lowenstein CJ: MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle. 8:712–715. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jung HB and Ahmad N: Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle. 8:1478–1483. 2009. View Article : Google Scholar : PubMed/NCBI
27	Han MK, Song EK, Gou Y, Ou X, Mantel C and Broxmeyer HE: SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell. 2:241–251. 2008. View Article : Google Scholar : PubMed/NCBI